Clinical study of Ganoderma lucidum extract in the treatment of motor and non motor symptoms in patients with early PD

Xuanwu Hospital of Capital Medical University0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•A) Meets the diagnostic criteria of clinically probable PD for primary Parkinson's disease of MDS;
•B) Age 30-80 at diagnosis of Parkinson's disease;
•C) H-Y clinical grade =2;
•D) UPDRS H2o between 10 and 30 points (10 and 30 points);
•E) The course of disease does not exceed 5 years;
•F) Is not receiving anti-Parkinson's drugs or other treatment, or has been discontinued for more than 2 weeks (including dopamine preparations, dopamine agonists, COMT inhibitors, MAO inhibitors, antan, amantadine);
•G) Agree to participate in this study, sign the informed consent, abide by the relevant experimental regulations, take medication on time and come for regular review;
•H) Agree to be treated only with experimental drugs for the next 1.5 years, and to take anti-Parkinson's drugs as prescribed if necessary.

•A) Patients with atypical or secondary Parkinson's disease;
•B) A history of psychiatric symptoms or mental illness;
•C) Cognitive impairment (MDSE =24);
•D) Participating in other drug trials within the past 3 months;
•E) Severe liver and renal function abnormalities (more than 3 times the normal mean);
•F) ongoing use of anti-Parkinson's drugs;
•G) Not to sign the informed consent

发起方

Xuanwu Hospital of Capital Medical University